Total Funding
22
18
Total FundingPost-IPO Equity raised
Growth Score
-28 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
225319
Athersys is a biopharmaceutical company that discovers and develops therapeutic products to treat several disease indications.
Robert Mays: Head of Neuroscience- Kasey Rosado: Interim Chief Financial OfficerPast Role: Ankura, Senior Managing Director
About the Company
Athersys is a biopharmaceutical company that discovers and develops therapeutic products to treat several disease indications. The company's product development portfolio includes MultiStem, a stem cell product, that is being developed as a treatment for multiple disease indications, is being evaluated in two ongoing clinical trials, and has
been authorized for use in a third clinical trial. In addition, Athersys develops pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy, or other forms of excessive daytime sleepiness.
